Bio-Techne Corp (TECH)
NEUTRALFundamental
53
Precio
$72.34
Capitalización Bursátil
$11.27B
Parte 1 · Cuánto vale la empresa
Resumen
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$1.21B
Últimos 12 meses (hasta 31/3/2026)
Beneficio Neto
$110M
Últimos 12 meses (hasta 31/3/2026)
Flujo de Caja Libre
$257M
Patrimonio Neto Total
$1.92B
Pasivo Total
$639M
Ratio de Liquidez
4.49
Cobertura de Intereses
15.88
Deuda/EBITDA
1.37
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$40.41
Precio Actual
$72.34
Margen de Seguridad
-79.0%
Rango de Valor Justo
$26.27 - $54.55
Métodos de Estimación
Métricas de Valoración
Ratio P/E
104.91
ROE
3.8%
Ratio P/B
5.44
P/FCF
42.04
Margen Bruto
65.0%
ROIC
5.1%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
5.1%
WACC
11.4%
ROIC − WACC
-6.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (15)
- Price CAGR 10.90%
- ROIC 5.1%
- Gross Margin 65.0%
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 10.6%
- Earnings Quality (OCF/NI) 2.69
- Share Dilution -0.3%
- Piotroski F-Score 5/9
Fallido (11)
- EPS shows upward trend
- EPS CAGR -10.63%
- P/FCF 42.04
- P/B Ratio 5.44
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 5.4%
- Analyst Consensus 41% Buy
- Earnings Surprise avg 0.7%
- Net Margin Trend 9.0% vs 10.9%
No disponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Kim Kelderman | CEO, President & Director | 57 |
| Mr. William A. Geist | President of Protein Sciences Segment | 56 |
| Dr. Gary J. Latham Ph.D. | VP & CTO | - |
| Mr. David Clair C.F.A. | Vice President of Investor Relations | - |
Riesgo de Auditoría
8
Riesgo del Consejo
1
Riesgo de Compensación
10
Riesgo de Derechos del Accionista
1
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for TECH, sourced from Markets Gazette.
- 6/15/2026POSITIVEActivist Investor Ananym Urges Bio-Techne to Consider Selling
Activist investor Ananym Capital Management has acquired a significant stake in Bio-Techne Corp., signaling a potential shift in the company's strategic direction. Ananym is actively urging the Bio-Techne board to initiate a comprehensive strategic review, with a primary focus on exploring a potential sale of the company. This development could lead to a substantial premium for shareholders if a sale materializes, as activist campaigns often aim to unlock shareholder value through such actions. Investors will be closely watching Bio-Techne's response and any subsequent strategic decisions.
- 3/13/2026NEGATIVEIs Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?
A significant wealth management firm has divested its entire stake in Bio-Techne Corporation, a developer of life sciences reagents and diagnostic solutions. While the specific reasons for the liquidation were not disclosed, the complete exit by a major investor raises concerns about potential headwinds or a reassessment of the company's future growth prospects. Investors will be closely watching for any further commentary from the firm or Bio-Techne management to understand the underlying drivers of this substantial sell-off, which could impact short-term sentiment and stock performance.
via Markets Gazette